Compare GRF & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GRF | GRML |
|---|---|---|
| Founded | 1989 | N/A |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.1M | 41.9M |
| IPO Year | N/A | 2022 |
| Metric | GRF | GRML |
|---|---|---|
| Price | $10.09 | $0.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.1K | ★ 3.0M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.47 | $0.27 |
| 52 Week High | $11.85 | $0.45 |
| Indicator | GRF | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 46.43 | 52.14 |
| Support Level | $9.96 | $0.31 |
| Resistance Level | $10.81 | $0.43 |
| Average True Range (ATR) | 0.14 | 0.06 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 46.11 | 68.53 |
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.